Cargando…

Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer

Durvalumab, an anti‐programmed cell death‐ligand 1 (PD‐L1) antibody, is currently used in the maintenance therapy for patients with stage III non‐small cell lung cancer after platinum‐based chemoradiotherapy. A 69‐year‐old male with lung adenocarcinoma, clinical stage IIIA, was treated with chemorad...

Descripción completa

Detalles Bibliográficos
Autores principales: Uemura, Takehiro, Fukumitsu, Kensuke, Maeno, Ken, Fukuda, Satoshi, Onuki, Tomohiro, Kanemitsu, Yoshihiro, Oguri, Tetsuya, Niimi, Akio, Hida, Toyoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374598/
https://www.ncbi.nlm.nih.gov/pubmed/34457312
http://dx.doi.org/10.1002/rcr2.835
_version_ 1783740151275454464
author Uemura, Takehiro
Fukumitsu, Kensuke
Maeno, Ken
Fukuda, Satoshi
Onuki, Tomohiro
Kanemitsu, Yoshihiro
Oguri, Tetsuya
Niimi, Akio
Hida, Toyoaki
author_facet Uemura, Takehiro
Fukumitsu, Kensuke
Maeno, Ken
Fukuda, Satoshi
Onuki, Tomohiro
Kanemitsu, Yoshihiro
Oguri, Tetsuya
Niimi, Akio
Hida, Toyoaki
author_sort Uemura, Takehiro
collection PubMed
description Durvalumab, an anti‐programmed cell death‐ligand 1 (PD‐L1) antibody, is currently used in the maintenance therapy for patients with stage III non‐small cell lung cancer after platinum‐based chemoradiotherapy. A 69‐year‐old male with lung adenocarcinoma, clinical stage IIIA, was treated with chemoradiotherapy. As the treatments progressed, his dry cough gradually subsided. After chemoradiotherapy had been completed, we started durvalumab administration. One month later, his dry cough relapsed and persisted. Based on the changes of his blood eosinophil counts, we clinically diagnosed him with asthma. A 71‐year‐old male with lung adenocarcinoma, clinical stage IIIB, was treated with chemoradiotherapy. After completing chemoradiotherapy, we initiated durvalumab administration. After 6 months, his dry cough was noticed to involve wheezing. Based on his spirometric values and the fraction of exhaled nitric oxide, a clinical diagnosis of asthma was established. Asthma should be considered as one of the possible side effects when immune checkpoint inhibitors are used in cancer treatment.
format Online
Article
Text
id pubmed-8374598
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-83745982021-08-26 Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer Uemura, Takehiro Fukumitsu, Kensuke Maeno, Ken Fukuda, Satoshi Onuki, Tomohiro Kanemitsu, Yoshihiro Oguri, Tetsuya Niimi, Akio Hida, Toyoaki Respirol Case Rep Case Reports Durvalumab, an anti‐programmed cell death‐ligand 1 (PD‐L1) antibody, is currently used in the maintenance therapy for patients with stage III non‐small cell lung cancer after platinum‐based chemoradiotherapy. A 69‐year‐old male with lung adenocarcinoma, clinical stage IIIA, was treated with chemoradiotherapy. As the treatments progressed, his dry cough gradually subsided. After chemoradiotherapy had been completed, we started durvalumab administration. One month later, his dry cough relapsed and persisted. Based on the changes of his blood eosinophil counts, we clinically diagnosed him with asthma. A 71‐year‐old male with lung adenocarcinoma, clinical stage IIIB, was treated with chemoradiotherapy. After completing chemoradiotherapy, we initiated durvalumab administration. After 6 months, his dry cough was noticed to involve wheezing. Based on his spirometric values and the fraction of exhaled nitric oxide, a clinical diagnosis of asthma was established. Asthma should be considered as one of the possible side effects when immune checkpoint inhibitors are used in cancer treatment. John Wiley & Sons, Ltd 2021-08-19 /pmc/articles/PMC8374598/ /pubmed/34457312 http://dx.doi.org/10.1002/rcr2.835 Text en © 2021 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Uemura, Takehiro
Fukumitsu, Kensuke
Maeno, Ken
Fukuda, Satoshi
Onuki, Tomohiro
Kanemitsu, Yoshihiro
Oguri, Tetsuya
Niimi, Akio
Hida, Toyoaki
Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer
title Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer
title_full Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer
title_fullStr Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer
title_full_unstemmed Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer
title_short Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer
title_sort asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374598/
https://www.ncbi.nlm.nih.gov/pubmed/34457312
http://dx.doi.org/10.1002/rcr2.835
work_keys_str_mv AT uemuratakehiro asthmacausedbydurvalumabafterchemoradiotherapyintwopatientswithnonsmallcelllungcancer
AT fukumitsukensuke asthmacausedbydurvalumabafterchemoradiotherapyintwopatientswithnonsmallcelllungcancer
AT maenoken asthmacausedbydurvalumabafterchemoradiotherapyintwopatientswithnonsmallcelllungcancer
AT fukudasatoshi asthmacausedbydurvalumabafterchemoradiotherapyintwopatientswithnonsmallcelllungcancer
AT onukitomohiro asthmacausedbydurvalumabafterchemoradiotherapyintwopatientswithnonsmallcelllungcancer
AT kanemitsuyoshihiro asthmacausedbydurvalumabafterchemoradiotherapyintwopatientswithnonsmallcelllungcancer
AT oguritetsuya asthmacausedbydurvalumabafterchemoradiotherapyintwopatientswithnonsmallcelllungcancer
AT niimiakio asthmacausedbydurvalumabafterchemoradiotherapyintwopatientswithnonsmallcelllungcancer
AT hidatoyoaki asthmacausedbydurvalumabafterchemoradiotherapyintwopatientswithnonsmallcelllungcancer